Navigation Links
Increased fertility rate for IVF patients achieved by new equipment design
Date:2/29/2012

A novel system for processing embryos during IVF treatment has been shown to significantly improve the chances of pregnancy by more than a quarter.

Pioneered by a Newcastle team of fertility experts at the University and within the NHS, the innovative design of interlinked incubators provides a totally enclosed and controlled environment within which every step of the IVF process can be performed.

Research published today in the journal PLoS ONE reveals that the introduction of the new system into the Newcastle Fertility Centre at Life, part of the Newcastle Hospitals NHS Foundation Trust, resulted in a 27% increase in pregnancy rate compared with conventional equipment used in IVF treatment labs.

Traditionally, in IVF procedures embryos are cultured in incubators, which provide a controlled environment. However, it is necessary to check embryo development under the microscope.

This generally involves removing them from the controlled environment of the incubators, which may be harmful. The system developed by the Newcastle team overcomes this problem by enabling all procedures to be conducted within an enclosed and controlled environment.

Initially the new system was tested extensively to make sure that it maintained stable environmental conditions (for air quality and temperature). Subsequent studies on embryos donated to research showed a significant increase in the proportion of embryos developing normally over a period of 6-7 days.

After introduction into the laboratories at Newcastle Fertility Centre at Life, the team were able to compare the treatment outcomes over a period of three years. The study, found that 45% achieved a clinical pregnancy compared to 32% and 35% in each of the preceding two years. This represents a minimum increase of 27% in the clinical pregnancy rate; a clinical pregnancy means that a heart beat was seen on the scan at 7 weeks gestation.

The study, which took account of variability between patients, included women aged 37 or less, undergoing their first cycle of IVF or ICSI, and who had more than ten ovarian follicles (the structures which contain a mature egg).

This is the first and only system of its kind to be installed in the UK, however, based on the innovative design from the Newcastle team, similar systems have already been exported to IVF clinics in the Netherlands, Canada and Thailand.

This positive benefit to IVF patients came from investment into cutting edge research in embryonic stem cell research and was funded by the Medical Research Council and One North East.

Newcastle University's Professor Mary Herbert who led the research team at Newcastle Fertility Centre at Life, part of the Newcastle Hospitals NHS Foundation Trust and based at the Centre for Life, said: "Our aim was to keep eggs and embryos in conditions similar to those they would experience naturally - inside a woman's body. This led our team to design and develop a system in which it is possible to perform all of the technical procedures while maintaining stable conditions throughout the IVF process."

Alison Murdoch, Professor of Reproductive Medicine who leads the clinical service at Newcastle Fertility Centre at Life said: "Growing good embryos is the key to IVF success and everyone, even those who have a very small prospect of success, deserve to have the best possible chance. Since installing this new technology over 850 babies have now been born."


'/>"/>

Contact: Karen Bidewell
karen.bidewell@ncl.ac.uk
44-191-222-6972
Newcastle University
Source:Eurekalert

Related biology technology :

1. Downsizing and the Need for Increased Selling Effectiveness Fuel Delta Points Growth
2. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
3. Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
4. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
5. US Dominance in Scientific Research Significantly Challenged by Increased Competition from Europe and Asia, According to Thomson Reuters Study
6. Proposition 19 Decision Prompts Cannabis Science to Anticipate Increased Demand for its Pharmaceutical Products for Critical Ailments and Begin the Formal Application Process for FDA Clinical Trials Immediately
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
9. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
10. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
11. Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
Breaking Biology News(10 mins):